The c.423C>A (p.Cys141Ter) variant in GP1BB is a nonsense variant that may cause loss of function of the protein, however it is predicted to escape nonsense mediated decay and remove >10% of the protein (PVS1_Strong). At least one patient (Patient ID.1 in PMID: 33657022) with this variant had multiplate aggregation data showing virtually absent ristocetin agglutination in the proband and their affected sibling, which is disproportional to aggregation with other agonists. Platelet function studies in this manuscript were performed by multiplate aggregation and not light transmission aggregometry which is the gold standard. The very low platelet counts, characteristic of BSS, explain why aggregation with other agonists are decreased and not normal as specified in the rule specifications for PP4. Additionally, the patient had excessive mucocutaneous bleeding. This pattern of results unequivocally supports a diagnosis of Bernard-Soulier Syndrome. This variant has been detected in at least 2 probands with Bernard-Soulier syndrome (Patient ID.1 in PMID: 33657022, Patient 1 in PMID: 22343686). Both individuals were homozygous for the variant (1 PM3 point, PM3). The variant has been reported to segregate in the proband plus two additional homozygous BSS affected family members (PMID:33657022), 2 PP1 points, PP1_Moderate). The MAF allele frequency in gnomAD v4.1.0 is 0.00002178 (based on 1/45916 alleles) in the Remaining population, which is lower than the ClinGen PD VCEP threshold (<0.00006517; PM2_Supporting). In summary, this variant meets the criteria to be classified as Pathogenic for autosomal recessive Bernard-Soulier syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PVS1_Strong, PP1_Moderate, PP4, PM2_Supporting and PM3 (VCEP specifications version 1.1).